|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc. |
First Approval Date24 Sep 2020 |
A RANDOMISED, PARALLEL, DOUBLE BLINDED STUDY TO COMPARE THE EFFICACY AND SAFETY OF FKB238 TO AVASTIN® IN 1ST LINE TREATMENT FOR PATIENTS WITH ADVANCED/RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN COMBINATION OF PACLITAXEL AND CARBOPLATIN
A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients with Advanced/Recurrent Non Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin - AVANA
A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin
The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer
100 Clinical Results associated with Centus Biotherapeutics Ltd.
0 Patents (Medical) associated with Centus Biotherapeutics Ltd.
100 Deals associated with Centus Biotherapeutics Ltd.
100 Translational Medicine associated with Centus Biotherapeutics Ltd.